ITGR Share Price | Integer Holdings Corp. Stock Analysis & Recommendation

Q: How big is Integer Holdings Corp.?

Market Cap: As of Jun 18, Integer Holdings Corp. has a market capitalization of 4,154.24 million, categorizing it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, Integer Holdings Corp. reported net sales of 1,755.28 million and a net profit of 78.04 million.Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 1,619.21 million and total assets of 3,077.97 million.

Q: What does Integer Holdings Corp. do?

Overview:Integer Holdings Corporation is a medical device outsource manufacturing company operating in the Pharmaceuticals & Biotechnology industry with a market cap of USD 4,154.24 Million.Financial Snapshot:Most recent Net Sales: 436 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -22 Million (Quarterly Results - Mar 2025) Market cap: USD 4,154.24 Million (Small Cap)Key Metrics:P/E: 45.00 Dividend Yield: 0.00% Debt Equity: 0.75 Return on Equity: 5.83% Price to Book: 2.59 Contact Details:Address: 5830 Granite Parkway., Suite 1150, PLANO TX : 75024 Tel: ['1 302 6587581', '1 716 7595809'] Fax: 1 302 6555049 Website: https://integer.net

Q: Is Integer Holdings Corp. technically bullish or bearish?

As of 24 October 2025, the technical trend for Integer Holdings Corp. has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages also indicate a bearish stance. The Bollinger Bands are bearish on both weekly and monthly time frames. Although the weekly RSI shows bullish momentum, it is not supported by other indicators, such as the KST and Dow Theory, which are bearish or show no trend. In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -44.98% versus the S&P 500's 15.47%. Overall, the current technical stance is bearish and indicates weakness in the stock's performance.

Q: Is Integer Holdings Corp. overvalued or undervalued?

As of 7 November 2025, the valuation grade for Integer Holdings Corp. has moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 45, a Price to Book Value of 2.63, and an EV to EBITDA ratio of 15.31. In comparison, Sanmina Corp., a peer, has a more attractive P/E ratio of 39.80, suggesting that Integer Holdings Corp. is trading at a premium relative to its industry peers.The company's recent stock performance has been notably poor, with a year-to-date return of -48.11%, significantly underperforming the S&P 500, which has returned 14.40% in the same period. This stark contrast further supports the conclusion that Integer Holdings Corp. is overvalued in the current market environment.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

202.94 k

Shareholding (Dec 2025)

FII

15.09%

Held by 132 FIIs

DII

18.5%

Held by 72 DIIs

Promoter

0.89%

How big is Integer Holdings Corp.?

22-Jun-2025

As of Jun 18, Integer Holdings Corp. has a market capitalization of $4.15 billion, with net sales of $1.76 billion and a net profit of $78.04 million over the last four quarters.

View full answer

What does Integer Holdings Corp. do?

22-Jun-2025

Integer Holdings Corporation is a medical device outsourcing manufacturer in the Pharmaceuticals & Biotechnology industry, with a market cap of approximately USD 4.15 billion. As of March 2025, it reported net sales of USD 436 million and a net profit of -USD 22 million.

View full answer

Who are in the management team of Integer Holdings Corp.?

22-Jun-2025

As of March 2022, the management team of Integer Holdings Corp. includes Bill Sanford (Independent Chairman), Joseph Dziedzic (CEO), and several independent directors: Pamela Bailey, James Hinrichs, Jean Hobby, Martin Maxwell, and Filippo Passerini. They oversee the company's strategic direction and operations.

View full answer

Is Integer Holdings Corp. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Integer Holdings Corp. is in a bearish trend, with negative indicators across multiple technical analyses, and has underperformed the S&P 500 significantly, showing a year-to-date return of -44.98%.

View full answer

Is Integer Holdings Corp. overvalued or undervalued?

11-Nov-2025

As of November 7, 2025, Integer Holdings Corp. is considered overvalued with a valuation grade of "expensive," reflected by a high P/E ratio of 45 and a year-to-date stock performance of -48.11%, significantly underperforming the S&P 500's 14.40% return.

View full answer

Compare Integer Holdings Corp. with Similar Stocks

iRhythm Technologies, Inc.LivaNova Plc ICU Medical, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Operating profit has grown by an annual rate 8.76% of over the last 5 years

The company declared negative results in Mar'25 after positive results in Dec'24

With ROCE of 8.55%, it has a very expensive valuation with a 1.93 Enterprise value to Capital Employed

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,894 Million (Small Cap)

P/E

28.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.67

Return on Equity

5.93%

Price to Book

1.66

Revenue and Profits:

Net Sales:

471 Million

(Quarterly Results - Dec 2025)

Net Profit:

49 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

10.23%

6 Months

-15.74%

1 Year

-25.96%

2 Years

-25.23%

3 Years

13.16%

4 Years

12.04%

5 Years

0.29%

Integer Holdings Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.49%

EBIT Growth (5y)

17.58%

EBIT to Interest (avg)

3.68

Debt to EBITDA (avg)

3.75

Net Debt to Equity (avg)

0.75

Sales to Capital Employed (avg)

0.63

Tax Ratio

28.87%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

6.40%

ROE (avg)

5.72%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.66

EV to EBIT

18.70

EV to EBITDA

11.69

EV to Capital Employed

1.39

EV to Sales

2.20

PEG Ratio

Dividend Yield

ROCE (Latest)

7.45%

ROE (Latest)

5.93%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 96 Schemes (65.43%)

Foreign Institutions

Held by 132 Foreign Institutions (15.09%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 4.18% vs 9.36% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 47.27% vs 25.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "470.90",
          "val2": "452.00",
          "chgp": "4.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "86.60",
          "val2": "94.60",
          "chgp": "-8.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "9.30",
          "val2": "13.20",
          "chgp": "-29.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.80",
          "val2": "-7.00",
          "chgp": "125.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "48.60",
          "val2": "33.00",
          "chgp": "47.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "108.50%",
          "val2": "145.30%",
          "chgp": "-3.68%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 7.37% vs 10.62% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -15.11% vs 35.91% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,846.50",
          "val2": "1,719.80",
          "chgp": "7.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "335.20",
          "val2": "339.80",
          "chgp": "-1.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "42.30",
          "val2": "56.40",
          "chgp": "-25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "5.70",
          "val2": "-23.30",
          "chgp": "124.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "102.80",
          "val2": "121.10",
          "chgp": "-15.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "113.30%",
          "val2": "135.30%",
          "chgp": "-2.20%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

470.90

452.00

4.18%

Operating Profit (PBDIT) excl Other Income

86.60

94.60

-8.46%

Interest

9.30

13.20

-29.55%

Exceptional Items

1.80

-7.00

125.71%

Consolidate Net Profit

48.60

33.00

47.27%

Operating Profit Margin (Excl OI)

108.50%

145.30%

-3.68%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 4.18% vs 9.36% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 47.27% vs 25.00% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

1,846.50

1,719.80

7.37%

Operating Profit (PBDIT) excl Other Income

335.20

339.80

-1.35%

Interest

42.30

56.40

-25.00%

Exceptional Items

5.70

-23.30

124.46%

Consolidate Net Profit

102.80

121.10

-15.11%

Operating Profit Margin (Excl OI)

113.30%

135.30%

-2.20%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 7.37% vs 10.62% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -15.11% vs 35.91% in Dec 2024

All Annual Results

Company CV

About Integer Holdings Corp.

Integer Holdings Corp.

Pharmaceuticals & Biotechnology

Integer Holdings Corporation, formerly Greatbatch, Inc., is a medical device outsource manufacturing company. The Company's segments include Medical and Non-Medical. Medical segment includes Portable Medical, Cardio & Vascular, and Cardiac & Neuromodulation product lines. Non-Medical segment includes Electrochem product line. It serves the cardiac, neuromodulation and vascular markets. It also serves the non-medical power solutions market. In addition, the Company develops batteries for niche applications in energy, military, and environmental markets. Its brands include Greatbatch Medical, Lake Region Medical and Electrochem. Its primary customers include multi-national original equipment manufacturers (OEMs) and their affiliated subsidiaries.

Company Coordinates

Company Details

5830 Granite Parkway., Suite 1150 , PLANO TX : 75024

Tel: 1 302 65875811 716 7595809

https://integer.net

Registrar Details